HGH (Somatropin)

Somatropin is not an analogue and not a fragment: it is recombinant human growth hormone, the full 191-residue sequence with both disulfide bridges, expressed in E. coli. That identity is why it functions as the reference compound in growth-hormone research rather than as a subject of it. Preclinical work using it is largely mechanistic — receptor dimerization at the GH receptor, JAK2 activation, STAT5 phosphorylation and translocation, and hepatic IGF-1 transcription downstream.

Rodent and cell work established the axis this catalogue's secretagogues are measured against. Hypophysectomised rat models demonstrated restoration of longitudinal growth; hepatocyte and cell-line studies mapped the signalling cascade; knockout and receptor-mutation models separated GH-direct effects from IGF-1-mediated ones, which remains the central methodological problem in the field because the two are difficult to disentangle in an intact animal.

The more relevant preclinical literature for anyone buying this material is analytical rather than pharmacological: recombinant somatropin aggregates, and dimer and oligomer content is the parameter that separates competently manufactured protein from poorly manufactured protein. Aggregated material is both less active and more immunogenic.

The clinical record is among the largest for any protein in this catalogue, and it is genuine. Somatropin holds regulatory approval from Health Canada, the FDA and the EMA for defined indications — paediatric growth hormone deficiency, Turner syndrome, Prader-Willi syndrome, chronic renal insufficiency, adult growth hormone deficiency and HIV-associated wasting among them — with decades of published trial data and post-marketing surveillance behind those approvals.

Adult GH-deficiency trials report changes in body composition, bone density and lipid parameters. Trials in non-deficient adults are a much smaller and more equivocal literature, and the distinction matters: replacing a deficient hormone and supplementing a sufficient one are different experiments with different results.

None of that record attaches to research-grade material. Approval covers a specific manufactured product characterised for identity, purity, aggregate content, sterility and potency, delivered under clinical supervision. Research material shares the intended molecule and none of the surrounding controls. A large clinical literature about somatropin is not a safety assurance for an unapproved supply of somatropin.

The claim that growth hormone reverses ageing is the one this compound is sold under most often, and it traces to a single small 1990 study in men over 60 that reported changes in lean mass and fat mass. Later controlled work and systematic review found modest body-composition changes accompanied by a substantial adverse-event rate, with no demonstrated improvement in functional outcomes such as strength or quality of life. The claim outran the evidence within a few years of the original paper and has not caught up since.

A second claim is that GH builds muscle in the way anabolic agents do. What the literature supports is an increase in lean body mass, a proportion of which is fluid retention rather than contractile tissue, and the strength data does not track the mass data.

A third is that IU figures are interchangeable between products. IU and milligram conversions depend on the manufacturer's reference standard, and material without a lot-specific quantitative result has no reliable potency figure at all.

Everything else on the growth-hormone shelf acts upstream of this molecule; this is the molecule. Tesamorelin and CJC-1295 are GHRH analogues that stimulate pituitary release, ipamorelin and GHRP-2 are ghrelin-receptor secretagogues doing the same through a second pathway. All of them depend on a functioning pituitary and produce pulsatile, feedback-regulated output. Somatropin bypasses the pituitary entirely and imposes an exogenous concentration, which is both its experimental value as a positive control and the reason its adverse-effect profile is heavier than the secretagogues'.

That difference is the whole comparison. Secretagogue studies read a regulated system being nudged; somatropin studies read the receptor being driven directly. Effect sizes are not comparable between the two designs, and a result obtained with somatropin does not predict what a secretagogue will do.

Against the IGF-1 arm, the distinction is one step further down the cascade: GH acts at its own receptor and IGF-1 output is a consequence, so the two cannot be substituted in any experiment attempting to separate direct from IGF-1-mediated effects.

The adverse-effect profile is documented rather than theoretical, which distinguishes this from most compounds here. Fluid retention, arthralgia, myalgia, peripheral oedema and carpal tunnel syndrome are dose-related and common. Insulin resistance and impaired glucose tolerance are established effects, and frank diabetes has been reported. Intracranial hypertension, gynaecomastia and, in susceptible individuals, acromegalic changes with prolonged excess exposure are recognised.

The oncological question is unresolved rather than settled in either direction. GH raises IGF-1, and epidemiological work associates higher IGF-1 with certain cancers; long-term follow-up of treated cohorts has produced mixed findings. Active malignancy is a contraindication in the approved labelling.

The material risks are specific to protein manufacture. Aggregated or dimerised somatropin is less active and more immunogenic; anti-hGH antibodies have been documented with poorly manufactured product. Counterfeit and underfilled vials are widespread in the grey market, and potency cannot be judged by appearance. A lot-specific result reporting purity and dimer content is the only check available, and it is why dimer content is measured on this product rather than purity alone.

Somatropin is a 22 kDa protein rather than a short synthetic peptide, and it is markedly less forgiving. Mechanical stress denatures it: reconstitute by directing diluent slowly against the vial wall, never onto the cake, and swirl — shaking generates the air-water interface where the protein unfolds and aggregates.

Lyophilized vials are stable refrigerated; reconstituted material belongs at 2–8 °C, protected from light, and must not be frozen. Freezing a reconstituted protein solution is the fastest route to aggregate formation, which is the failure mode that matters here because aggregation is both an activity loss and an immunogenicity hazard.

Cloudiness, visible particulates or fibrils in a reconstituted vial indicate aggregation and the material should be discarded rather than characterised further. Potency figures in IU rest on the manufacturer's reference standard, so quantitative work should be anchored to the lot-specific certificate rather than to the label.